Back to Journals » Research and Reports in Transdermal Drug Delivery » Volume 4

Revisiting transdermal scopolamine for postoperative nausea and vomiting

Authors Pergolizzi J, Raffa RB, Zampogna G, Annabi HM, Pallaria TJ, Taylor R

Received 17 April 2015

Accepted for publication 19 May 2015

Published 13 August 2015 Volume 2015:4 Pages 35—44


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Narasimha Murthy

Video abstract presented by Hani Michael Annabi

Views: 1127

Joseph V Pergolizzi,1–3 Robert B Raffa,4 Gianpietro Zampogna,5 Hani Michael Annabi,6 Thomas J Pallaria,7 Robert Taylor,5,6

1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, 3Association of Chronic Pain Patients, Houston, TX, 4Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, 5NEMA Research, Bonita Springs, FL, 6Public Health Department, Johns Hopkins University Krieger School of Arts and Sciences, Baltimore, MD, 7Department of Anesthesia, Barnabas Health-Newark Beth Israel Medical Center, Newark, NJ, USA

Abstract: Postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) in ambulatory patients remain serious problems that affect a substantial subset of surgical patients. Guidelines recommend that patients be stratified for risk, and patients at moderate-to-high risk be administered prophylactic PONV/PDNV therapy. Risk stratification on the four-point Apfel scale assigns one point for each of the following: female sex, nonsmoking status, history of PONV or motion sickness, and the use of postoperative opioids. Patients who score 2 or higher are considered to be at moderate-to-high risk. Other risk factors have been evaluated and discussed in the literature, such as type and duration of surgery. Surprisingly, although PONV/PDNV is more common in the first 24 hours after anesthesia, it may occur for days following surgery, and so, continuous treatment is advantageous. Transdermal scopolamine is a well-established agent with a history of safety and efficacy for PONV/PDNV prevention. Scopolamine is an anticholinergic agent that is generally well tolerated; side effects tend to be mild to moderate. The most frequently reported side effects with transdermal scopolamine are visual disturbances and dry mouth. Once adhered to the skin, the patch administers an initial dose and then a continuous dose of medication over 72 hours. Transdermal scopolamine is easy to administer, safe, effective, and relatively cost-effective, and it should be considered as an important tool to help prevent PONV/PDNV, whether administered as monotherapy or in combination with other agent(s).

Keywords: transdermal scopolamine, postoperative nausea and vomiting, antiemetic

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

Pergolizzi Jr JV, Raffa RB, Pappagallo M, Fleischer C, Pergolizzi, III J, Zampogna G, Duval E, Hishmeh J, LeQuang JA, Taylor R Jr

Patient Preference and Adherence 2017, 11:107-119

Published Date: 17 January 2017

Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain

Pergolizzi Jr JV, van de Laar M, Langford R, Mellinghoff H-U, Morón Merchante I, Nalamachu S, O'Brien J, Perrot S, Raffa RB

Journal of Pain Research 2012, 5:327-346

Published Date: 29 August 2012

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011